Cryoport, Inc.
CYRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CYRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions for the cell and gene therapy industry, supporting clinical trials and commercial therapies globally.
Key risk: Dependence on cell and gene therapy approvals
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$814.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Cryoport, Inc. provides temperature-controlled supply chain solutions for the cell and gene therapy industry, supporting clinical trials and commercial therapies globally.
- As of June 30, 2026, Cryoport supported 779 clinical trials (94 in Phase 3) and 22 commercial therapies [sec_mda · as of 2026-08-06].
- Cash and equivalents were $269.3M as of June 30, 2026 [sec].
- Total revenue for the six months ended June 30, 2026 was $49.0M, with a net loss of $8.3M [sec].
- Life Sciences Services segment represented over 67% of total revenue in 2024, up from approximately 62% in 2023 [sec · filed 2025-04-25].
What works
- Cryoport is a leading provider of temperature-controlled supply chain solutions for cell and gene therapies, with a growing base of clinical trials and commercial therapies [sec_mda · as of 2026-08-06].
- Revenue from supporting cell and gene therapy clinical trials grew 14.8% year-over-year for the six months ended June 30, 2026 [sec_mda · as of 2026-08-06].
- The company maintains a strong cash position of $269.3M as of June 30, 2026, with minimal debt of $0.9M [sec].
What to weigh
- Cryoport reported a net loss of $8.3M for the six months ended June 30, 2026, indicating ongoing unprofitability [sec].
- The company's performance is heavily dependent on the success and regulatory approval of cell and gene therapies, which are uncertain and long-cycle [sec_mda · as of 2026-08-06].
- Life Sciences Products revenue growth was modest at 6.7% for the six months ended June 30, 2026, compared to the prior period [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cryoport supported 779 clinical trials and 22 commercial therapies as of June 30, 2026.
“As of June 30, 2026, we supported 779 clinical trials, of which 94 were in Phase 3, and 22 commercial therapies.”
SEC MD&A · August 6, 2026
Revenue from CGT clinical trials grew 14.8% year-over-year for the six months ended June 30, 2026.
“Revenue from the support of CGT clinical trials was $26.3 million for the six months ended June 30, 2026, representing a 14.8% year-over-year increase from $22.9 million in the prior period.”
SEC MD&A · August 6, 2026
Life Sciences Services segment grew to over 67% of total revenue in 2024.
“Our Life Sciences Services business continued to expand in 2024, and now represents over 67% of total revenue, compared to approximately 62% in 2023.”
SEC filings · April 25, 2025
Risks & what to watch (3)›
Key risks
- Dependence on cell and gene therapy approvals — Revenue growth relies on clinical trial success and regulatory approvals of advanced therapies, which are uncertain [sec_mda · as of 2026-08-06].
- Continued net losses — The company reported a net loss of $8.3M for the six months ended June 30, 2026, with no clear timeline to profitability [sec].
- Integration and restructuring risks — Forward-looking statements reference risks related to acquisitions, divestitures (e.g., CRYOPDP), and cost realignment plans [sec_mda · as of 2026-08-06].
What to watch
- Progress of the 779 clinical trials supported, especially the 94 in Phase 3, as they advance toward potential commercial launches [sec_mda · as of 2026-08-06].
- Trends in Life Sciences Services revenue growth, which now constitutes the majority of total revenue [sec · filed 2025-04-25].
- Cash burn rate and path to profitability, given the net loss of $8.3M on $49.0M revenue for the six months ended June 30, 2026 [sec].
Sources: SEC filings · SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run Cryoport, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cryoport, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.54 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 13 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
165
Total value held
$395.8M
| Holder | Shares | Value |
|---|---|---|
| cadian capital management, lp | 4,776,343 | $39.5M |
| morgan stanley | 4,576,730 | $37.9M |
| vanguard capital management llc | 4,237,712 | $35.1M |
| blackrock, inc. | 3,980,898 | $33.0M |
| millennium management llc | 2,970,464 | $24.6M |
| fred alger management, llc | 1,699,379 | $14.1M |
| first eagle investment management, llc | 1,489,698 | $12.3M |
| mak capital one llc | 1,423,265 | $11.8M |
| geode capital management, llc | 1,248,135 | $10.3M |
| mirova | 1,158,277 | $9.6M |
Showing top 10 of 165 institutional holders of Cryoport, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 5.3%
- Days to cover
- 5.0
- Shares short
- 2,202,556
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cryoport, Inc.?
Cryoport, Inc. provides temperature-controlled supply chain solutions for the cell and gene therapy industry, supporting clinical trials and commercial therapies globally.
Who is the CEO of Cryoport, Inc.?
Mr. Jerrell W. Shelton is the chief executive officer of Cryoport, Inc. (CYRX).
Where is Cryoport, Inc. headquartered?
Cryoport, Inc. (CYRX) is headquartered in Brentwood, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.